The positive interim results from the Phase 1/2 study of LX1001 indicate potential efficacy in treating Alzheimer's Disease, which could lead to increased investor confidence and a positive impact on Lexeo's stock price. The study's findings of dose-dependent increases in APOE2 expression and improvements in tau biomarkers are significant, as they suggest the treatment's potential effectiveness. Additionally, the treatment's good tolerance profile further supports its potential success.